Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
McKesson
Medtronic
Boehringer Ingelheim
Merck

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Veledimex

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Veledimex?

Veledimex is an investigational drug.

There have been 8 clinical trials for Veledimex. The most recent clinical trial was a Phase 2 trial, which was initiated on June 28th 2019.

The most common disease conditions in clinical trials are Glioblastoma, Breast Neoplasms, and Scleroderma, Systemic. The leading clinical trial sponsors are Ziopharm, Fibrocell Technologies, Inc., and [disabled in preview].

There are eighteen US patents protecting this investigational drug and one hundred and eighty-four international patents.

Recent Clinical Trials for Veledimex
TitleSponsorPhase
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive GlioblastomaZiopharmPhase 2
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized SclerodermaFibrocell Technologies, Inc.Phase 1/Phase 2
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102ZiopharmPhase 1

See all Veledimex clinical trials

Clinical Trial Summary for Veledimex

Top disease conditions for Veledimex
Top clinical trial sponsors for Veledimex

See all Veledimex clinical trials

US Patents for Veledimex

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Veledimex   Start Trial Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof Intrexon Corporation (Blacksburg, VA)   Start Trial
Veledimex   Start Trial Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex Intrexon Corporation (Blacksburg, VA)   Start Trial
Veledimex   Start Trial Process of preparing chiral diacylhydrazine ligands Intrexon Corporation (Blacksburg, VA)   Start Trial
Veledimex   Start Trial Modified forms of Pseudomonas exotoxin A Intrexon Corporation (Blacksburg, VA)   Start Trial
Veledimex   Start Trial Crystalline diacylhydrazine and the use thereof Intrexon Corporation (Blacksburg, VA)   Start Trial
Veledimex   Start Trial Boron-containing diacylhydrazines Intrexon Corporation (Blacksburg, VA)   Start Trial
Veledimex   Start Trial Methods and compositions for diagnosing disease Intrexon Corporation (Blacksburg, VA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Veledimex

Drugname Country Document Number Estimated Expiration Related US Patent
Veledimex Australia 2008307643 2027-09-28   Start Trial
Veledimex Brazil PI0817233 2027-09-28   Start Trial
Veledimex Canada 2715080 2027-09-28   Start Trial
Veledimex China 101868241 2027-09-28   Start Trial
Veledimex European Patent Office 2205249 2027-09-28   Start Trial
Veledimex Israel 204731 2027-09-28   Start Trial
Veledimex Japan 2010540534 2027-09-28   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Moodys
Boehringer Ingelheim
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.